Gilead Sciences, Inc.

Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes therapeutic products primarily in the areas of virology, oncology, and inflammation. Its portfolio includes antiretroviral treatments for HIV, direct‑acting antivirals for hepatitis C and hepatitis B, and investigational agents for various cancers. The company sells its medicines in North America, Europe, Asia, and other regions through a combination of direct sales forces and distribution partners. Gilead’s research efforts are concentrated on small‑molecule drugs and biologics that target specific viral pathways.

The organization maintains research and development sites in the United States, Europe, and Asia, and operates manufacturing facilities that support global supply chains. Its corporate headquarters is located in Foster City, California, United States of America. Gilead’s products are prescribed by clinicians in hospitals, outpatient clinics, and specialty care settings worldwide. The company collaborates with academic institutions, government agencies, and other pharmaceutical firms to advance clinical trials and expand access to its therapies.

Gilead is recognized for its specialization in antiviral drug development, having brought to market several first‑in‑class treatments for HIV and hepatitis C that altered standard of care. The antiviral remdesivir, initially investigated for Ebola, received emergency use authorization for COVID‑19 and became a focal point of the 2020 phishing incident described in the source material. The firm also maintains a strong regulatory compliance infrastructure to meet the requirements of the U.S. Food and Drug Administration, the European Medicines Agency, and other health authorities. Its scientific expertise in virology and medicinal chemistry is frequently cited in peer‑reviewed literature and conference presentations.

Structurally, Gilead Sciences, Inc. is a publicly traded corporation listed on the NASDAQ under the ticker symbol GILD and is incorporated in the State of Delaware. The company wholly owns several subsidiaries that handle regional commercialization, manufacturing, and intellectual property management. It is not a subsidiary of another larger entity and operates as an independent organization with a board of directors overseeing corporate governance. Ownership is distributed among institutional investors, mutual funds, and individual shareholders who hold its common stock.